ResMed | RMD - Ebit

Stock Price
42.35
Daily Change
0.43 1.01%
Monthly
-2.68%
Yearly
14.42%
Q3 Forecast
42.03

ResMed reported $456.57M in EBIT for its fiscal quarter ending in June of 2025.



Financials
Stock Price USD
Assets USD 8.17B
Cash and Equivalent USD 1.21B
Cost of Sales USD 518.56M
Current Assets USD 3.51B
Current Liabilities USD 1.02B
Debt USD 851.81M
Dividend Yield USD 0.82
EBIT USD 456.57M
EBITDA USD 530.86M
Employees USD 8.16K
EPS Earnings Per Share USD 2.58
Equity Capital and Reserves USD 5.97B
Gross Profit on Sales USD 829.44M
Interest Expense on Debt USD 775K
Interest Income USD 59K
Loan Capital USD 658.39M
Market Capitalization USD 43.89B
Net Income USD 379.7M
Operating Expenses USD 891.42M
Operating Profit USD 456.57M
Ordinary Share Capital USD 146.39M
PE Price to Earnings USD 28.85
Pre-Tax Profit USD 458.05M
Sales Revenues USD 1.35B
Selling and Administration Expenses USD 265.12M
Stock USD 975.96M
Trade Creditors USD 278.16M
Trade Debtors USD 990.67M

Ebit Change Date
Ansell USD 117.3M 39.1M Jun/2024
Avita Medical AUD -10272000 22.56M Dec/2024
Cochlear AUD 275M 25.5M Dec/2024
CSL USD 2.75B 1.35B Dec/2024
Fisher & Paykel Healthcare NZD 291.5M 73.4M Mar/2025
Healius AUD 23.7M 26M Dec/2024
Integral Diagnostics AUD 24.99M 5.08M Jun/2024
Mayne Pharma AUD -16200000 13.2M Jun/2024
Nanosonics AUD 8.7M 2.6M Dec/2024
Polynovo AUD 840K 147K Jun/2024
Ramsay Health Care AUD 500.1M 14.8M Dec/2024
Regis Healthcare AUD 44.36M 13.1M Dec/2024
ResMed USD 456.57M 20.65M Jun/2025
Sigma Healthcare AUD 6.86M 2.15M Jul/2024
Sonic Healthcare AUD 423.94M 80.3M Dec/2024
Telix Pharmaceuticals AUD 37.44M 16.38M Dec/2024